Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
37 hedge funds and large institutions have $9.5M invested in Regulus Therapeutics in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 10 closing their positions.
6,900% more call options, than puts
Call options by funds: $70K | Put options by funds: $1K
64% more capital inflows, than outflows
Capital inflows: $5.53M | Capital outflows: $3.38M
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
5.71% less ownership
Funds ownership: 26.38% → 20.67% (-5.7%)
10% less funds holding
Funds holding: 41 → 37 (-4)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DAFNA Capital Management
Los Angeles,
California
|
+$2.47M |
| 2 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
+$591K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$65.1K |
| 4 |
Two Sigma Advisers
New York
|
+$61.9K |
| 5 |
Two Sigma Investments
New York
|
+$24.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$2.45M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$271K |
| 3 |
Morgan Stanley
New York
|
-$248K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$170K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$73K |
RGLS Hedge Fund Activity: Q4 2021 in Review
37 of the 6,521 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q4 2021, worth a combined $9.5M — down 40% from $15.9M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of RGLS and 7 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 8 added.
The largest buyer was DAFNA Capital Management, opening a new position worth an estimated $2.47M. The largest seller was Endurant Capital Management, exiting entirely with an estimated $2.45M sold.
- 37 institutional investors held Regulus Therapeutics (RGLS) as of Q4 2021, down from 41 in Q3 2021.
- Funds reported $9.5M of Regulus Therapeutics stock for Q4 2021, down 40% quarter-over-quarter.
- 7 funds opened new Regulus Therapeutics positions in Q4 2021 and 10 closed out, a net change of -3 holders.
- The largest Regulus Therapeutics buyer in Q4 2021 was DAFNA Capital Management, an estimated $2.47M added.
- The largest Regulus Therapeutics seller in Q4 2021 was Endurant Capital Management, an estimated $2.45M sold.
Based on aggregated 13F filings for Q4 2021.